BNP Paribas Financial Markets purchased a new stake in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 60,079 shares of the company's stock, valued at approximately $461,000. BNP Paribas Financial Markets owned approximately 0.16% of iTeos Therapeutics at the end of the most recent reporting period.
Several other large investors have also recently modified their holdings of ITOS. Virtus ETF Advisers LLC grew its position in iTeos Therapeutics by 58.2% during the 4th quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company's stock valued at $69,000 after purchasing an additional 3,293 shares during the last quarter. SG Americas Securities LLC increased its position in shares of iTeos Therapeutics by 12.2% during the fourth quarter. SG Americas Securities LLC now owns 13,866 shares of the company's stock valued at $106,000 after acquiring an additional 1,508 shares in the last quarter. Wells Fargo & Company MN raised its holdings in iTeos Therapeutics by 16.9% in the 4th quarter. Wells Fargo & Company MN now owns 16,644 shares of the company's stock worth $128,000 after acquiring an additional 2,402 shares during the last quarter. US Bancorp DE lifted its position in iTeos Therapeutics by 40.1% in the 4th quarter. US Bancorp DE now owns 16,919 shares of the company's stock valued at $130,000 after acquiring an additional 4,843 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new stake in iTeos Therapeutics during the 4th quarter valued at $142,000. Hedge funds and other institutional investors own 97.16% of the company's stock.
Insider Buying and Selling
In other iTeos Therapeutics news, major shareholder Ansbert Gadicke sold 1,031,931 shares of the company's stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total value of $8,317,363.86. Following the completion of the transaction, the insider now directly owns 3,452,797 shares in the company, valued at $27,829,543.82. This represents a 23.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of the stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $8.06, for a total transaction of $5,079,339.46. Following the completion of the sale, the insider now directly owns 2,108,594 shares of the company's stock, valued at approximately $16,995,267.64. This trade represents a 23.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. 12.50% of the stock is owned by insiders.
iTeos Therapeutics Price Performance
Shares of NASDAQ:ITOS traded down $0.03 during trading on Tuesday, hitting $8.53. The company's stock had a trading volume of 969,530 shares, compared to its average volume of 571,202. The firm has a market cap of $326.48 million, a price-to-earnings ratio of -2.71 and a beta of 1.39. The company has a 50-day moving average of $6.76 and a 200-day moving average of $7.37. iTeos Therapeutics, Inc. has a 12 month low of $4.80 and a 12 month high of $18.13.
iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last released its quarterly earnings results on Monday, April 28th. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($0.94) by $0.14. As a group, research analysts anticipate that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current year.
Analysts Set New Price Targets
A number of research analysts have recently issued reports on the company. HC Wainwright downgraded iTeos Therapeutics from a "buy" rating to a "neutral" rating in a report on Wednesday, May 14th. Wedbush reiterated an "outperform" rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a report on Wednesday, March 5th. Raymond James set a $12.00 target price on shares of iTeos Therapeutics in a research note on Wednesday, May 14th. Leerink Partners reissued a "market perform" rating and set a $9.00 price objective (down from $47.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Finally, Wells Fargo & Company restated an "overweight" rating and issued a $13.00 target price (down previously from $16.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $17.86.
Check Out Our Latest Stock Report on ITOS
About iTeos Therapeutics
(
Free Report)
iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
Further Reading
Before you consider iTeos Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iTeos Therapeutics wasn't on the list.
While iTeos Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
